多西紫杉醇/顺铂化疗同步放疗对局部晚期非小细胞肺癌疗效观察

目的研究多西紫杉醇/顺铂化疗同步放疗对晚期非小细胞肺癌的疗效及毒副作用。方法76例Ⅲ期非小细胞肺癌患者被随机分为两组,多西紫杉醇/顺铂化疗同步放疗组(同步组), 多西紫杉醇/顺铂化疗序贯放疗组(序贯组)；两组放疗方法相同,放疗剂量DT 60～70Gy,每次2Gy,每周5次,化疗方案为多西紫杉醇40mg/m²，第1、8天用药，顺铂20mg/d，第1、5天用药。21天为一周期。同步组化疗第1天即开始放疗，序贯组在化疗2周期后放疗。结果同步组和序贯组的有效率分别为65.7%和41.5%(P＜0.05),两组的完全缓解率分别为17.1%和7.3%(P＞0.05) ,放射性肺炎及食管炎发生率同步组高于序贯组(P＜0.05)。结论放疗同步多西紫杉醇/顺铂化疗治疗晚期非小细胞肺癌疗效优于序贯化放疗方法,副反应虽增加,但可耐受。

Concurrent chemoradiotherapy with docetaxel/cisplatin for local advanced non-small cell lung cancer

To evaluate the efficacy and side effects of concurrent radiotherapy and chemotherapy with docetaxel/cisplatin for local advanced non-small cell lung cancer (NSCLC). Methods A total of 76 patients with stage Ⅲ NSCLC were randomly divided into two groups: the docetaxel/cisplatin chemotherapy concurrent radiotherapy group(concurrent group) and the docetaxel/cisplatin chemotherapy sequential radiotherapy group(sequential group). In the two groups, the radiation method was the same, five times a week at 2 Gy per day up to a total dose of 60-70Gy. Chemotherapy consisted of docetaxel 40mg/m2 d1，8 and cisplatin 20mg/d, on day 1 and 5, lasting 21 days. The concurrent group received radiotherapy on day 1 of chemotherapy, while the sequential group received radiotherapy after 2 chemotherapy cycles. ResultsThe response rate in the concurrent group was 65.7% and 41.5% in sequential group (P<0.05). The complete response rate was 17.1% in the concurrent group and 7.3% in sequential group (P>0.05). The acute toxic effects such as radiation esophagitis were more severe in the concurrent group than in the sequential group (P<0.05). ConclusionConcurrent radiotherapy and chemotherapy with docetaxel/cisplatin is an effective regimen for advanced non small cell lung cancer with increased but tolerable toxic effects.